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  37 
NEW & NOTEWORTHY 38 
1. What is New?  39 
• Free radicals from vascular mitochondria with advancing age play a critical role in attenuating 40 
NO bioavailability and, subsequently, promote endothelial dysfunction in the skeletal feed 41 
arteries (SMFAs) of the elderly. 42 
• Mitochondria-targeted antioxidant, MitoQ, acutely restores SMFA endothelial function in the 43 
old to that of the young. 44 
2. What is Relevant? 45 
• Scavenging free radicals from within the mitochondria of the vasculature with mitochondria-46 
targeted antioxidants reverses age-related vascular dysfunction which is a linked to 47 
cardiovascular disease. 48 
3. Summary 49 
• Mitochondria-targeted antioxidants, such as MitoQ, may be a useful pharmacological therapy 50 
in terms of counteracting the vascular dysfunction so often associated with advancing age and 51 
cardiovascular disease (CVD). 52 
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ABSTRACT 69 
 70 
This study sought to determine the role of free radicals derived from mitochondria in the 71 
vasculature in the recognized age-related endothelial dysfunction of human skeletal muscle feed 72 
arteries (SMFAs). A total of 44 SMFAs were studied, 18 from young (32±6 yrs) subjects in 73 
control conditions and 26 from old (75±7 yrs) subjects with and without acute exposure to the 74 
mitochondria-targeted antioxidant MitoQ and nitric oxide synthase (NOS) blockade.  The 75 
relative abundance of SMFA proteins from the electron transport chain (ETC), phosphorylated 76 
(p-) to endothelial (e) NOS ratio, manganese superoxide dismutase (MnSOD), and the 77 
mitochondria-derived superoxide (O2-) production were assessed. Endothelium-dependent and -78 
independent SMFA vasodilation was assessed in response to flow-induced shear stress, 79 
acetylcholine (ACh), and sodium nitroprusside (SNP). The ETC proteins were lower in the old 80 
and were not altered by MitoQ. MitoQ restored endothelium-dependent vasodilation in the old to 81 
that of the young when stimulated by both flow (Young: 68±5; Old: 25±7; Old+MitoQ 65±9 %) 82 
and ACh (Young: 97±4; Old: 59±10; Old+MitoQ: 98±5 %), but did not alter, the initially 83 
uncompromised, endothelium-independent vasodilation (SNP). Compared to the young, MitoQ 84 
in the old attenuated the initially elevated mitochondria-derived O2- production and increased the 85 
initially attenuated level of MnSOD. Furthermore, MitoQ increased the ratio of p-eNOS/NOS 86 
and the restoration of endothelium-dependent vasodilation in the old by MitoQ was ablated by 87 
NOS blockade. Thus, free radicals derived from mitochondria in the vasculature of the elderly 88 
appear to play a critical role in attenuating NO bioavailability and, subsequently, endothelial 89 
dysfunction with advancing age. (Words 253) 90 
 91 
 92 
 93 
 94 
ABBREVIATIONS LIST 95 
 96 
SMFAs, skeletal muscle feed arteries; NOS, nitric oxide synthase; ETC, electron transport chain;  97 
MnSOD, manganese superoxide dismutase; O2-, superoxide; ACh, acetylcholine; SNP, sodium 98 
nitroprusside; NO, nitric oxide; TPP, triphenylphosphonium; L-NMMA, Nω-nitro-L-arginine 99 
methyl ester; PSS, physiological saline solution; ONOO-, peroxynitrite; CVD, cardiovascular 100 
disease 101 
 102 
INTRODUCTION 103 
 104 
With advancing age, blood flow to skeletal muscle is often diminished (24, 31), which, at least in 105 
part, is likely a consequence of attenuated endothelial function in the skeletal muscle resistance 106 
vasculature (9, 33, 34). However, the specific mechanism(s) responsible for the age-related 107 
attenuation of skeletal muscle blood flow is currently not well understood. The study of human 108 
SMFAs is highly germane to better understanding the vascular biology of aging, as it affords the 109 
opportunity to examine endothelial function in vessels that, in terms of skeletal muscle blood 110 
flow, also have regulatory potential (18). Indeed, our group has recently documented that the 111 
vasodilatory function of SMFAs obtained from elderly human subjects was markedly attenuated 112 
and this functional decline was associated with a decrease in the ratio of p-eNOS to total eNOS 113 
protein levels (29). Although attenuated NO bioavailability with advancing age may depend on 114 
multiple factors that regulate NO production and degradation, free radicals, principally O2- (2, 14, 115 
21), likely play an important role by reacting rapidly with NO, thereby decreasing NO 116 
bioavailability (21, 37). Currently, the exact source of the free radicals that appear to attenuate 117 
NO bioavailability and subsequent endothelial dysfunction with advancing age remain unclear.  118 
Mitochondria play a critical role in cellular function in both health and disease, but are also an 119 
important and major source of free radicals (22, 35). Interestingly, although mitochondrial 120 
content is relatively low in vascular endothelial cells and smooth muscle (2-5% of cell volume) 121 
compared to physically active skeletal muscle and cardiac myocytes (5-35 % of cell volume) 122 
(11), previous studies have revealed a strong correlation between mitochondria-derived oxidative 123 
stress and endothelial dysfunction (2, 8, 35).  Interestingly, our group recently documented that 124 
exercise training induces an increase in vascular mitochondrial respiratory capacity, evidence of 125 
improved redox balance, and elevated basal NO bioavailability (30). These data suggest that age- 126 
and disease-related alterations in arterial function may be directly affected by the function, and 127 
subsequent free radical production, of mitochondria in the vasculature. Therefore, strategies to 128 
constrain mitochondria-derived free radical levels to within typical physiological levels may 129 
prove useful in attenuating the development of endothelial dysfunction with age.  130 
The first line of defense against free radicals is both endogenous and exogenous antioxidants. 131 
However, to date, antioxidant supplementation (e.g. Vitamin C) has not proven effective at 132 
specifically decreasing mitochondria-derived free radical production (1, 19). Of note, as 133 
mitochondria are negatively charged, the incorporation of a lipophilic cation, such as 134 
triphenylphosphonium (TPP), to a potent antioxidant, such as the active ubiquinol moiety of 135 
Coenzyme Q10, enables the selective and extensive accumulation of the antioxidant within the 136 
mitochondria (26, 27). Utilizing this approach, a commercially available mitochondria-targeted 137 
antioxidant, MitoQ (MitoQ Limited, Auckland, NZ), has been synthesized to yield a thousand-138 
fold greater concentration within the mitochondria than untargeted antioxidants, which distribute 139 
throughout the cell (26, 27). The use of MitoQ to specifically treat age-related endothelial 140 
function is supported by a recent, elegant and comprehensive, study by Gioscia-Ryan et al., (15) 141 
who reported that this mitochondria-targeted antioxidant attenuated endothelial dysfunction in 142 
older mice. Nevertheless, age-related vascular mitochondrial free radical production and 143 
endothelial dysfunction in humans has yet to be examined.  144 
Consequently, utilizing the pressure myography technique and incubation with MitoQ, 145 
this study sought to determine the role of free radicals derived from vascular mitochondria in the 146 
age-related endothelial dysfunction of human SMFAs. We tested the hypothesis that free radicals 147 
derived from vascular mitochondria play a critical role in attenuating NO bioavailability and, 148 
subsequently, promote endothelial dysfunction in the elderly. 149 
METHODS 150 
Subjects and general procedures: A total of 44 SMFAs were obtained from young and old 151 
subjects, from the axillary and inguinal regions, during melanoma-related surgeries. From these 152 
SMFAs, endothelial-dependent and -independent vascular function was assessed in 10 young 153 
subjects, while 16 old subjects were assessed with and without MitoQ. A subset of these vessels 154 
(n = 8 young and 8 old subjects) were assessed for mitochondria-specific O2- production. 155 
Endothelial-dependent vascular function was assessed in the SMFAs from the remaining 8 young 156 
subjects, while the remaining 10 old subjects were assessed with and without MitoQ and Nω-157 
nitro-L-arginine methyl ester (L-NMMA). Unused segments of these vessels (n = 8 young and 158 
10 old subjects) were used for immunoblotting. It should be noted that, although all subjects 159 
were free from cancer and chemotherapy, there were no other specific exclusion criteria for this 160 
study. However, all medical conditions and medications were noted. All protocols were 161 
approved by the Institutional Review Boards of the University of Utah and Salt Lake City 162 
Veteran’s Affairs Medical Center (VAMC), carried out in accordance with the Declaration of 163 
Helsinki, and written informed consent was obtained from all subjects prior to surgery.  164 
Vessel harvest and preparation: SMFAs (outer diameter ~500 μm, length 1-2 cm) from the 165 
axillary (e.g. serratus anterior or latissimus dorsi muscles) and inguinal (e.g. hip adductors or 166 
quadriceps femoris muscles) regions, obtained during sentinel node biopsy for melanoma surgery 167 
at the Huntsman Cancer Hospital and the Salt Lake City VAMC, were studied. Patients were 168 
anaesthetized using a general protocol: propofol, fentanyl, benzodiazepines, and succinylcholine 169 
(28).  SMFAs were harvested during dissection to locate sentinel lymph nodes, for clinical 170 
analysis, and were identified and classified based upon being a vascular inlet into a muscle bed, 171 
structure, coloration, and pulsatile bleed pattern (17). SMFAs were ligated, excised, and 172 
immediately placed in iced normal physiological saline solution (PSS) before being transferred 173 
to the laboratory within 15 min of harvesting (29). 174 
MitoQ treatment and vessel function protocols: Initially, perivascular adipose and/or 175 
connective tissue around the SMFAs was removed under a dissecting microscope (SZX10; 176 
Olympus, Center Valley, PA, USA) in cold (4 °C) PSS containing (mM): 145.0 NaCl, 4.7 KCL, 177 
2.0 CaCl2, 1.17 MgSO4, 5.0 glucose, 2.0 pyruvate, 0.02 EDTA, 3.0 MOPS buffer and 1 g (100 178 
mL)-1 BSA at pH 7.4. SMFA function was assessed in pressure myography organ baths (110p; 179 
DMT Systems, Aarhus, Denmark) (29). The arteries were cannulated at both ends with 180 
micropipette tips and then pre-incubated for 30 min within the bath in either PSS, the control 181 
condition, or MitoQ mesylate (10 μM). After the pre-incubation period, the vessel outer 182 
diameters were recorded using an inverted microscope with a video camera (TS100; Nikon 183 
Eclipse, Melville, NY, USA), with data streamed in real time to edge detection software (DMT 184 
VAS v 0.2.0), monitored at a sampling rate of 1 kHz. Fluid leak was detected by pressurizing the 185 
vessel to an intraluminal pressure set of 60 mmHg, closing the cannulas to the fluid reservoirs, 186 
and assessing any change in vessel diameter. Arteries, free from leaks were then warmed to 37°C, 187 
allowed to develop spontaneous tone for a 30 min equilibration period, and then vasodilatory 188 
function was assessed (29).  189 
Vasodilation assessments: Vasodilatory dose response curves (%) were assessed for three 190 
stimuli: First, to assess the endothelium-dependent vasodilatory response to flow-induced shear 191 
stress, intraluminal flow was developed. This was achieved by altering the heights of the 192 
independent fluid reservoirs, contiguous with both cannulated ends of the SMFAs, in equal and 193 
opposite directions so that a pressure difference was developed across the vessel without altering 194 
mean intraluminal pressure. Three pressure differences of 15, 30, and 45 mmHg, which yielded 195 
an approximate flow rate of 15, 30 and 45 μl/min, were utilized for the flow experiments. Second, 196 
to assess endothelium-dependent vasodilation pharmacologically, an ACh dose response curve 197 
(ACh, 10-7 to 10-3 M) was performed following pre-constriction with phenylephrine (PE) (10-6 to 198 
10-4 M) to ~70 % of the maximum PE response. Third, to assess endothelium-independent 199 
vasodilation, a SNP dose response curve was performed (10-9 to 10-4 M) following pre-200 
constriction with PE (10-6 to 10-4 M) to ~70 % of the maximum PE response.  201 
Mitochondria-specific O2- measurements: Mitochondria-specific O2- measurements were 202 
performed with EPR spectroscopy on the initially frozen SMFA segments using an EMX X-band 203 
spectrometer (Bruker, MA). Briefly, the segment of the frozen SMFA was placed into a micro 204 
centrifuge tube containing 150 μL of the mitochondria-specific O2- spin trap mitoTempo-H 205 
(Enzo Life Sciences San Diego, CA) (1-hydroxy-4 [2-(triphenylphosphoino) – acetamido] - 206 
2,2,6,6-tetramethylpiperidine) (0.5 mmol/L) and incubated for 60 minutes at 37 ºC, facilitating 207 
the “thaw and trap” approach (10, 32).   The samples were then placed on ice and 50 µL of the 208 
solution was loaded into a capillary tube for EPR spectroscopy analysis.  The EPR spectroscopy 209 
scan was run with a center field at approximately g = 2.004 and the area under the curve of the 210 
spectra was calculated by double integration (29).  211 
Percent vasodilation calculations: Percent vasodilation was used for data expression to account 212 
for baseline differences in vessel diameter, and calculated using the following equation:  213 
(DT-Dp/Di-Dp)×100 214 
Where DT is the recorded diameter at a given time point, Dp is the diameter recorded after the 215 
addition of the vasoactive agent (i.e. pre-constriction diameter), and Di is the diameter recorded 216 
immediately before the addition of the vasoactive agent (initial diameter).   217 
Immunoblotting: The relative abundance of proteins for the ETC complexes, p- and eNOS, and 218 
MnSOD were determined in SMFAs using Western blot analysis. Briefly, SMFAs were 219 
homogenized in lysis buffer, supplemented with a protease/phosphate inhibitor cocktail (10 μM 220 
sodium fluoride and 1 mM phenyl methyl sulfonyl fluoride (PMSF)) (Santa Cruz Biotech, Santa 221 
Cruz, CA). Protein concentration was determined using the Bradford technique. 50 μg of 222 
homogenate was separated by polyacrylamide gel electrophoresis, transferred onto a 223 
nitrocellulose membrane, and incubated with primary and secondary antibodies directed against 224 
the proteins of interest. Membranes were imaged on a ChemiDoc XRS (Bio-Rad, Hercules, CA) 225 
and quantified with Image Lab software (Bio-Rad). The specific antibodies used to detect SMFA 226 
proteins included: Total OXPHOS Human Western Blot Antibody Cocktail (ab110411, Abcam, 227 
Cambridge, MA), total eNOS (610296, BD Transduction, San Jose, CA), p-eNOS at Ser1177 228 
(9570, Cell Signaling, Boston, MA), and superoxide dismutase 2 (SOD2) (SC-515068, Santa 229 
Cruz Biotech, Santa Cruz, CA). The abundance of each protein was normalized to beta-actin 230 
(ab8227, Abcam, Cambridge, MA), which served as a loading control. 231 
Statistical Analyses: The statistical analyses were performed using GraphPad Prism 7 Software 232 
(La Jolla, CA). Two-way repeated measures ANOVA was used to assess changes in vessel 233 
diameter with and without MitoQ in response to flow, ACh, and SNP. Two-way repeated 234 
measures ANOVA were used to assess changes in vessel diameter with and without MitoQ and 235 
with and without L-NMMA in response to flow and ACh. When necessary, a Tukey’s post hoc 236 
test was used to identify significant differences.  For all other comparisons, one-way ANOVA 237 
was used to assess the group and, if necessary, a Tukey’s post hoc test was used to identify the 238 
significant differences. For all analyses, a p-value of < 0.05 was considered significantly 239 
different. All data are expressed as mean ± SEM.   240 
RESULTS 241 
Subject characteristics: From the 44 SMFAs that were harvested, 18 were from young subjects 242 
(33±2 yrs) and 26 were from old subjects (72±5 yrs). The subject characteristics, obtained from 243 
preoperative examination of medical records, are presented in Table 1. Note that users of cancer-244 
related medications were excluded from the study. Also, it should be noted that all blood 245 
chemistry and complete blood count results (Table1) were within normal ranges, suggesting that 246 
the subjects who participated in this study were relatively healthy.  247 
Vessel characteristics: SMFAs were harvested from either the inguinal (n=23) or axial (n=21) 248 
regions from either males (n=25) or females (n=19). In agreement with our previous 249 
observations, vessel function was not different as a consequence of anatomic origin or sex. 250 
Immunoblotting, to assess the relative abundance of proteins in the ETC, revealed that the 251 
majority of the mitochondrial respiratory complexes, with the exception of Complex V, were 252 
significantly attenuated in the SMFAs of the old compared to the young (Figure 1). MitoQ did 253 
not alter this attenuation of the mitochondrial respiratory complexes in the old (Figure 1).  Basal, 254 
unpressurized, outer diameter of the SMFAs was not statistically different in the young, old, and 255 
old with MitoQ (Young: 510 ± 12 um; Old: 514 ± 15 um; Old+MitoQ: 515 ± 10 um). 256 
Additionally, maximal outer diameter of the SMFAs, achieved by Ca2+ free NPSS incubation, 257 
was not statistically different in the young, old, and old with MitoQ (Young: 758 ± 19 um; Old: 258 
752 ± 14 um; Old+MitoQ: 750 ± 15 um).  259 
The vasodilatory response to flow, ACh, and SNP and the impact of MitoQ in the old: The 260 
PE-induced pre-constriction of the SMFAs prior to the flow stimulus was similar between groups 261 
(Young: 69 ± 4 %, Old: 67 ± 5 %, Old+MitoQ: 68 ± 5, P > 0.05). The greatest vasodilation in 262 
response to the intraluminal flow of 45 ± 3 ul/min was significantly attenuated in the old 263 
compared to the young (Young: 68 ± 5; Old: 25 ± 7%, P < 0.05) (Figure 2A). However, the 264 
vasodilatory response to flow in the old was restored to that of the young by MitoQ (Old+MitoQ: 265 
65 ± 9 %) (Figure 2A). This effect of MitoQ in the old was also evident at the lower intraluminal 266 
flow rates of 15 ± 2 and 30 ± 4 μl/min (Figure 2A).  267 
The PE-induced pre-constriction of the SMFAs prior to the ACh and SNP dose response 268 
curves were similar between groups (Young: 69 ± 4 %; Old Control: 68 ± 5 %; Old + MitoQ 69 269 
± 5 %, P > 0.05). The greatest vasodilation in response to the highest dose of ACh (10-3 M) was 270 
significantly attenuated in the old compared to the young ACh (Young: 97±4 %; Old: 59±10 %, 271 
P < 0.05) (Figure 2B). However, the vasodilatory response to ACh in the old was restored to that 272 
of the young by MitoQ (Old+MitoQ: 98±5 %) (Figure 2B). This effect of MitoQ in the old was 273 
clearly evident across the whole ACh dose response curve (Figure 2B).  In contrast, endothelial-274 
independent vasodilatory function, the vasodilatory response to the highest dose of SNP (10-4 M) 275 
(Young: 97 ± 4 %, Old: 100 ± 11 %; Old+MitoQ: 98 ± 4 %, P > 0.05) and across the whole dose 276 
response curve, was similar among the young, old, and old with MitoQ (Figures 2C). 277 
Levels of mitochondria-specific O2- and MnSOD and the impact of MitoQ in the old: The 278 
baseline EPR spectroscopy signal for the mitoTempo-H adduct in the SMFAs, an index of 279 
mitochondria-specific O2- production, was greater in the old compared to the young (Young: 1.7 280 
± 0.2; Old: 6 ± 1.8; AUC/mg, P < 0.05) (Figures 3A). However, MitoQ significantly lowered 281 
SMFA O2- production in the old, such that the old were similar to the youg (Old+MitoQ: 1.95 ± 282 
0.7; AUC/mg) (Figure 3A). In terms of antioxidant status, immunoblotting revealed that baseline 283 
MnSOD protein content was significantly attenuated in the old compared to the young (Young: 284 
100 ± 18; Old: 38 ± 17 AUC, P < 0.05) (Figure 3B).  However, incubation with MitoQ 285 
significantly increased the MnSOD protein content of the old (Old+MitoQ: 78 ± 15 AUC) 286 
(Figure 3B). 287 
The role of NO bioavailability and the impact of MitoQ in the old: Immunoblotting revealed 288 
that the extent of eNOS phosphorylation, measured as the p-eNOS/eNOS ratio on the Western 289 
blots, was significantly lower in the old compared to the young (Young: 100 ± 16; Old: 35 ± 18; 290 
AUC P < 0.05). However, MitoQ enhanced the extent of eNOS phosphorylation in the old 291 
(Old+MitoQ: 59 ± 18 AUC) (Figure 4). SMFA vasodilation, in response to both flow and 292 
increasing doses of ACh, again revealed attenuated endothelial-dependent vasodilation in the old 293 
which could be restored acutely by MitoQ (Figure 5A and B). However, the impact of the MitoQ 294 
was negated by NOS blockade (Figure 5A and B). Furthermore, in the presence of L-NMMA the 295 
vasodilatory response to both flow and ACh with and without MitoQ was attenuated to a level 296 
that was significantly lower than the initial dose response in the old (Figure 5A and B). 297 
 298 
  299 
DISCUSSION 300 
This study sought to determine the role of free radicals derived from mitochondria in the 301 
vasculature in the age-related endothelial dysfunction documented in human SMFAs. The main 302 
hypothesis tested by this investigation was that free radicals derived from aging vascular 303 
mitochondria play a critical role in attenuating NO bioavailability and, subsequently, promote 304 
endothelial dysfunction in the elderly. The current findings strongly support this postulate and, of 305 
importance, translate previous findings in an animal model to humans. Specifically, despite the 306 
observation that the ETC proteins were lower in the old, and this was not altered by MitoQ, this 307 
mitochondria-targeted antioxidant acutely restored SMFA endothelium-dependent vasodilation, 308 
in response to both flow and ACh, to that of the young. Additionally, MitoQ attenuated 309 
mitochondria-derived O2- production, likely sparing MnSOD, which resulted in an increase in 310 
MnSOD levels. Furthermore, in the old, the restoration of SMFA endothelium-dependent 311 
vasodilation by MitoQ was ablated by NOS blockade, and MitoQ increased the extent of eNOS 312 
phosphorylation. Thus, augmented mitochondrial free radical production in the SMFAs of the 313 
elderly appears to play a critical role in attenuating NO bioavailability and, subsequently, 314 
promoting endothelial dysfunction with advancing age.  315 
Vascular aging, SMFAs, free radicals, and NO bioavailability:  316 
In terms of the vascular biology of aging, the study of human SMFAs is pertinent, as it affords 317 
the opportunity to examine endothelial function in vessels that, in terms of skeletal muscle blood 318 
flow, also have regulatory potential (18). In fact, our group recently documented that the 319 
endothelial function of SMFAs attained from the elderly was markedly attenuated and this 320 
functional decline was associated with a decrease in the ratio of p-eNOS to total eNOS protein 321 
level, emphasizing the likely role of attenuated NO bioavailability (29). Here, the findings of this 322 
previous work were confirmed with further evidence that aging similarly attenuates both flow- 323 
and ACh-mediated vasodilation in SMFAs (Figure 2A and B), each indicators of endothelium-324 
dependent vasodilation. The current findings further suggest that this limited vasodilatory 325 
capacity with advancing age is, at least in part, due to attenuated NO bioavailability, as again 326 
evidenced by a decrease in the ratio of p-eNOS to total eNOS protein expression in the SMFAs 327 
from the old (29) (Figure 4). Attenuated NO bioavailability with advancing age depends on 328 
multiple factors that regulate NO production and degradation, with a key role being played by 329 
free radicals. For example, O2- decreases NO bioavailability (2, 14, 21) by rapidly reacting with 330 
NO to form peroxynitrite (ONOO-), but then, in turn, ONOO- may oxidise the essential co-factor 331 
for eNOS, tetrahydrobiopterin, resulting in O2- production, rather than NO, by eNOS (21, 37). 332 
This redox imbalance likely plays an important role in the age-related fall in NO bioavailability, 333 
supported in this study by the greater mitochondria-derived O2- production and reciprocally 334 
attenuated MnSOD levels in the old SMFAs (Figure 3A and B). Indeed, there is accumulating 335 
evidence that increased free radical production leads to endothelial dysfunction with advancing 336 
age both in animals and humans, and that the resultant oxidative stress promotes vascular disease 337 
(7, 25, 39).  338 
MitoQ, age-related vascular dysfunction, and NO bioavailability: 339 
The acute 1 hr incubation of the SMFAs from the old with MitoQ effectively reversed the age-340 
related vascular dysfunction (Figure 2A and B). Several lines of evidence from this study suggest 341 
that this restoration of vascular function in the old SMFAs was NO mediated. First, MitoQ 342 
greatly attenuated mitochondrial O2- production to more closely resemble that of the young 343 
(Figure 3A), a change that would likely result in an increase in NO bioavailability. Again, it is 344 
interesting to note that this fall in O2- production was accompanied by an increase in MnSOD 345 
(Figure 3B). This makes intuitive sense and suggests a MitoQ-induced sparing of this 346 
endogenous antioxidant that targets O2- and is found predominantly within the mitochondria. 347 
Second, MitoQ significantly increased the attenuated ratio of p-eNOS to total eNOS protein 348 
expression in the SMFAs from the old (Figure 4), indicative of rescuing the activity of this NO 349 
producing pathway. Third, the reversal of the age-related vascular dysfunction achieved by 350 
MitoQ during both the flow and ACh dose response curves was ablated by NOS blockade, 351 
confirming a role for NOS in the MitoQ-induced response. Furthermore, the flow and ACh 352 
responses with and without MitoQ, in combination with NOS blockade, were significantly 353 
attenuated compared to the flow and ACh assessments in the old SMFAs. Overall, this indicates 354 
that NO still plays a role in the response of the old vessels, but, more importantly, that MitoQ 355 
was ineffectual when NOS was blocked, implying an NO-mediated mechanism of action (Figure 356 
2A and B). Although performed in stroke-prone hypertensive rats, the conclusion by Graham et 357 
al. (16) that MitoQ supplementation, initiated prior to the establishment of cardiovascular disease 358 
(CVD) in young animals, prevented the development of endothelial dysfunction by maintaining 359 
NO bioavailability, is in agreement with the premise of the current findings. 360 
Vascular aging, SMFAs, blood flow, and oxygen transport: 361 
It is widely accepted that aging is commonly associated with impaired blood flow, and 362 
subsequently oxygen delivery, to skeletal muscle during dynamic exercise and that this is likely 363 
caused by a combination of compromised cardiac output (17, 23) and attenuated peripheral 364 
vascular conductance with age (23, 25). In terms of the skeletal muscle vasculature, in rodent 365 
studies, the rate of endothelium-dependent vasodilation in the skeletal muscle arterioles, which 366 
are downstream from the SMFAs, and microcirculatory blood flow was attenuated in old 367 
compared to young animals (3, 4), subsequently impairing oxygen delivery to the contracting 368 
muscles. In humans, our group recently provided evidence supporting the contention that human 369 
SMFAs, the inlets to the muscle bed upstream of the arterioles, regulate vascular resistance, and 370 
therefore skeletal muscle perfusion, in response to shear stress and pharmacological vasodilators 371 
(17, 29). Furthermore, our group has also demonstrated that SMFAs from older humans exhibit 372 
an attenuated magnitude of endothelium-dependent vasodilation and delayed vasodilation 373 
kinetics in response to shear stress and ACh (29). In agreement with these prior results, the 374 
current findings confirm that the endothelium-dependent vasodilatory capacity of SMFAs, 375 
assessed by flow-induced shear stress and the response to ACh, is clearly attenuated with 376 
advancing age (Figure 2A and B). This attenuated SMFA vasodilation with aging is likely one of 377 
the mechanisms responsible for the age-related decline in blood flow and oxygen transport to 378 
active skeletal muscle during physical activity in the elderly. In light of the current positive 379 
findings with MitoQ and the positive impact on age-related vascular function, additional studies 380 
examining the effect of mitochondria-targeted antioxidants on skeletal muscle blood flow during 381 
exercise in the elderly are warranted.  382 
Mitochondrial health, vascular aging, and MitoQ  383 
As the major energy producers for most physiologic processes, well-functioning, healthy, 384 
mitochondria are essential for both systemic and cellular homeostasis. However, in addition to a 385 
central role in energy production, mitochondria seem to be important in terms of molecular 386 
signaling and cellular secretion in the vasculature and this is mediated, at least to some extent, by 387 
free radicals (8, 11). Indeed, free radicals, produced at numerous sites within the mitochondria, 388 
including Complexes I, II, and III of the ETC, play a critical role in these processes. For example, 389 
it has been documented that mitochondria located in the endothelial cytoskeleton of arterioles, in 390 
the human myocardium, produce free radicals in response to shear stress induced cell 391 
deformation, which are critical  for flow-mediated dilation (20).  Conversely, several recent 392 
studies have also revealed that mitochondria-derived free radicals in the vasculature play a 393 
critical role in peripheral vascular dysfunction with advancing age (15, 36, 38). Interestingly, and 394 
along these lines, both hyperglycemia and elevated triglycerides, recognized as inducers of 395 
endothelial dysfunction and atherosclerosis, increase mitochondria-derived free radicals and alter 396 
mitochondrial dynamics in vascular endothelial cells. This vascular dysfunction can be reversed 397 
by normalizing the blood sugar and lipid load, removing the mitochondrial stimulus (6). 398 
Furthermore, and perhaps somewhat ironically, in terms of mitochondrial health, mitochondria-399 
derived free radicals lower the abundance of MnSOD, which resides in the mitochondrial matrix, 400 
and negatively impacts mitochondrial biogenesis and mitochondrial content (15).  401 
The initial age-related findings from this study support the link between attenuated vascular 402 
function with advancing age (Figure 2A and B) and compromised vascular mitochondrial health, 403 
as evidenced by the greater O2- production (Figure 3A), lower levels of MnSOD (Figure 3B), and 404 
the attenuation of the ETC complexes (Figure 1) in the SMFAs from the old. Interestingly, in 405 
addition to restoring endothelial function in the SMFAs from the old (Figure 2A and B), the 406 
acute 1 hour incubation with MitoQ both decreased mitochondrial O2- production (Figure 3A) 407 
and restored mitochondrial antioxidant capacity (MnSOD) (Figure 3B). However, MitoQ did not 408 
impact the relative abundance of ETC complex proteins (Figure 1). This is of particular 409 
relevance in light of recent studies that have suggested aging is associated with attenuated 410 
mitochondrial respiratory complexes (12) and that elevated mitochondria-derived free radical 411 
production damages the mitochondrial DNA that encodes the ETC complexes (5, 13). This 412 
damage, predominantly at complex I, appears to directly affect electron transport and disrupts the 413 
whole mitochondrial respiratory cycle (5, 13). In the current study, although perhaps not 414 
surprising, due to the relatively short time course of the MitoQ exposure, the lack of effect on the 415 
significantly attenuated ETC complex protein expression is an important observation. 416 
Specifically, this documents that the positive impact of MitoQ on vessel function and 417 
mitochondrial free radical production is not dependent upon more long-term changes in the 418 
relative abundance of the mitochondrial complexes. 419 
Conclusion  420 
This study has demonstrated that, in human SMFAs, recognized to have regulatory potential, the 421 
attenuation of free radicals from the mitochondria in the vasculature, with a mitochondria-422 
targeted antioxidant, reverses age-related vascular dysfunction by what appears to be an NO-423 
dependent mechanism. These findings suggest that mitochondria-targeted antioxidants, such as 424 
MitoQ, may have utility in terms of counteracting the attenuated skeletal muscle blood flow and 425 
vascular dysfunction so often associated with advancing age and cardiovascular disease. 426 
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FIGURE LEGENDS 455 
Figure 1. The relative abundance of skeletal muscle feed artery proteins from the electron 456 
transport chain (ETC) of young subjects and old subjects with and without MitoQ. The 457 
ETC protein expression was normalized by β-actin protein expression. Data are expressed as 458 
mean ± SE. n = 10 young and 16 old subjects. * Significantly different from young, P<0.05. 459 
Figure 2. The vasodilatory dose response curves of skeletal muscle feed arteries from young 460 
subjects and old subjects with and without MitoQ evoked by flow, acetylcholine (ACh), and 461 
sodium nitropruside (SNP). Data are expressed as mean ± SE. n = 10 young and 16 old 462 
subjects. * Significantly different from old, P<0.05.  463 
Figure 3. Mitochondria-specific superoxide production and manganese superoxide dismutase 464 
(MnSOD) protein expression in skeletal muscle feed arteries of young subjects and old 465 
subjects with and without MitoQ. Superoxide levels were assessed utilizing the mitochondrial-466 
specific superoxide spin trap mitoTempo-H and electron paramagnetic resonance (EPR) 467 
spectroscopy. The EPR signal was expressed as the area under the curve (AUC) in arbitrary units 468 
and representative spectra are inlayed. The MnSOD protein expression was normalized by β-469 
actin protein expression. Data are expressed as mean ± SE. n = 8 young and 8 old subjects for 470 
EPR and n = 8 young and 10 old subjects for immunoblotting. MnSOD expression of young, old, 471 
old + MitoQ. * Significantly different from young and old+MitoQ, P<0.05; ǂ Significantly 472 
different from young, P<0.05.  473 
Figure 4. The relative abundance of proteins for endothelial NOS (eNOS) and 474 
phosphorylated (p-) eNOS at Ser1177 from skeletal muscle feed arteries of young subjects 475 
and old subjects with and without MitoQ. Data are expressed as mean ± SE. n = 8 young and 476 
10 old subjects. * Significantly different from young and old+MitoQ, P<0.05; ǂ Significantly 477 
different from young, P<0.05.  478 
Figure 5. The vasodilatory dose response curves of skeletal muscle feed arteries from young 479 
subjects and old subjects both with and without MitoQ and with and without nitric oxide 480 
synthase blockade (L-NMMA) evoked by both flow and acetylcholine (ACh). Data are 481 
expressed as mean ± SE. n = 8 young and 10 old subjects.  * Significantly different from young 482 
and old+MitoQ, P < 0.05; † Significantly different from all other groups and conditions, P< 0.05.  483 
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Table 1. Subject characteristics. 
  
   
Young (n=18)     Old (n=26) 
Age (year) 32±6 75±7 * 
Sex (male/female, n) 10/8 15/11 
Height (cm) 175±15 165±12 
Body mass (kg) 74±13 81±10 
BMI (kg m-2) 21±7 27±7 
Systolic blood pressure (mmHg) 116±7 126±9 
Diastolic blood pressure (mmHg) 78±5 81±9 
Glucose (mg dl-1) 110.8±9.2 108±5.2 
Blood urea nitrogen (mg dl-1) 17.4±5.0 16.8±6.4 
Creatinine (mg dl-1) 0.9±0.7 1±0.9 
Albumin (g dl-1) 4.2±0.6 4.2±0.7 
Lactate dehydrogenase (U L-1) 505.4±40.1 503±47.3 
Hemoglobin (g dl-1) 15.5±1.2 14.3±1.5 
White blood Cells (thousands per microliter, K ul-1) 4.9±2.1 7.7±1.4 
Red blood Cells (millions per microliter, M ul-1) 5.2±1.3 4.8±1.5 
Platelets (K ul-1) 255.9±21.1 240±27.2 
Hematocrit (%) 41.4±3.1 40±5 
Lymphocytes (%) 34.3±3.3 33±8.5 
Monocytes (%) 8.6±1.6 8.1±2.5 
Medications (Users/n) 
Diuretics 0/18 2/26 
Angiotensin- converting enzyme inhibitors 0/18 2/26 
Diabetic drugs 0/18 3/26 
Statins 0/18 2/26 
   
Data are expressed as mean ± SE or number of subjects (of the total number; n). 
*Significantly different from young subjects, P<0.05  
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